Spartha Medical received € 2.4 million in funding from the European Innovation Council to initiate clinical evaluation of its multifunctional coating solutions.
Spartha Medical, a French medtech start-up specializing in the development of multifunctional antimicrobial, antiviral and anti-inflammatory coatings, announced that it has received € 2.4 million ($ 2.75 million) in grants and an additional undisclosed equity financing from the European Innovation Council (EIC) Fund. The funds will be used to initiate the clinical evaluation of Spartha Medical's multifunctional coatings, which have been shown to inactivate resistant bacteria and viruses, including SARS-CoV-2.
Spartha Medical is among the 99 innovative European companies participating in the EIC Accelerator program selected at the end of 2021 to receive a grant.
“Spartha Medical is thrilled to have the support of the EIC fund, which we will use to launch clinical trials, strengthen our infrastructure and hire new talent,” said Dr Nihal Engin Vrana, CEO of Spartha Medical. “We are set to achieve the necessary regulatory compliance steps, including ISO certification, as well as start researching the next-generation of coatings. These will propel us to the forefront in preventing post-operative infections and in fighting against resistant bacteria. By consolidating our current co-development programs and partnerships and the development of new business opportunities, our aim is to become the market leader in customized coating development services, using a platform supported by Artificial Intelligence.”
Coatings for the medical sector
The antimicrobial, antiviral and anti-inflammatory properties make Spartha Medical coatings range suitable for the use in many surgical and patient care applications. The range is also able to counter SARS-CoV-2 (Covid-19). Furthermore, Spartha Medical coatings are a unique non-antibiotic-based solution, derived from natural biopolymers which make it biocompatible and applicable to all kinds of surfaces. The antibacterial effect occurs by contact on the polymer-coated surfaces.
With this key feature, the coating can be used on medical devices without affecting their primary function or can act as a physical antibacterial/antiviral barrier, which makes it easier to enable application on implants for at-risk patients. The company also offers a customised coating development service that optimises specific formulations to the needs of the client’s product.
Spartha Medical is currently preparing a clinical trial to evaluate its medical coating kit, which has antimicrobial properties with dedicated instrumentation, for use in surgery and other patient care settings. In addition, the company is also working on a consumer product with antimicrobial and antiviral properties, designed for daily use in personal and surface hygiene areas.